EGFR and metastatic colorectal cancer: In recent years, corroborating evidence has established epidermal growth factor receptor (EGFR) inhibitors to provide a distinct clinical benefit for patients with Rat sarcoma proto-oncogene (RAS) wild-type metastatic colorectal cancer (mCRC) [4,5,6,7,8,9].